- Sartorius Stedim Biotech press release ( OTCPK:SDMHF ): 9M GAAP EPS of €6.58.
- Revenue of €2.6B (+23.2% Y/Y).
- Sales revenue up 17.0% in constant currencies, underlying EBITDA margin at 35.0%.
- Outlook for 2022 specified : Sales revenue growth now expected to be in the lower half of the previous range of 15% to 19%; projection for underlying EBITDA margin unchanged at more than 35%.
- The CAPEX ratio is anticipated to be about 14.5% and net debt to underlying EBITDA is now anticipated to be about 0.8 at year end (previously about 0.2) following the closing of the Albumedix acquisition.
For further details see:
Sartorius Stedim Biotech 9M GAAP EPS of €6.58, revenue of €2.6B; updates FY22 guidance